AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...
Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced this week that the US Food and Drug Administration...
Yifan Pharma Secures NMPA Approval for Generic Sedapain
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that it has received marketing approval...
Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...
Shanghai Kehua Bioengineering Launches Xi’an Medical Complex Project
Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a leading Chinese biotechnology company, has announced plans...
HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy
Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc.,...
NMPA Optimizes Drug Manufacturing License Process with Digital QR Codes
The National Medical Products Administration (NMPA) has announced new measures to optimize the drug manufacturing...
Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU
German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing...
Aidea Pharma Terminates COVID-19 Drug Collaboration with PharmaBlock
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the termination of its development collaboration...
Daiichi Sankyo and AstraZeneca’s Datroway Approved in EU for Breast Cancer
Japan-based Daiichi Sankyo (TYO: 4568) and UK major AstraZeneca (NASDAQ: AZN) announced that their co-developed...
IDT and Shanghai Bioscience Forge Partnership to Drive Local Innovation in China
Integrated DNA Technologies (IDT), a leading life sciences and diagnostics company under the Danaher Corporation...
Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD...
Winsunny Pharma’s FY101 Gains NMPA Clinical Approval for Hyperlipidemia
China-based Beijing Winsunny Pharmaceutical Co., Ltd (SHA: 601089) announced that it has received clinical approval...
HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation
Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996),...
Zhifei Biological Gains Bangladesh Approval for Dysentery Vaccine Trial
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has received clearance from the Directorate General...
Hengrui Pharmaceuticals’ Vunakizumab Approved for Ankylosing Spondylitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
CSPC Pharmaceutical’s JMT108 Gains FDA Approval for Advanced Malignant Tumor Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...
Amgen’s Uplizna Approved by FDA for IgG4-Related Disease
US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the...
J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment
The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...
TJ Biopharma Partners with Biogen on Felzartamab Phase III Studies in China
China-based TJ Biopharma has entered into an agreement with US-based Biogen Inc. (NASDAQ: BIIB) to...